Geode Capital Management
GRCL

Geode Capital Management’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Geode Capital Management’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-43,334
Closed -$435K – 4691
2023
Q4 		$435K Hold
43,334
– – ﹤0.01% 3664
2023
Q3 		$125K Buy
43,334
+5,968
+16% +$21.8K ﹤0.01% 4168
2023
Q2 		$142K Buy
37,366
+4,202
+13% +$11.8K ﹤0.01% 4200
2023
Q1 		$61.7K Hold
33,164
– – ﹤0.01% 4473
2022
Q4 		$76K Hold
33,164
– – ﹤0.01% 4487
2022
Q3 		$106K Hold
33,164
– – ﹤0.01% 4544
2022
Q2 		$182K Hold
33,164
– – ﹤0.01% 4329
2022
Q1 		$77K Buy
33,164
+7,026
+27% +$23.9K ﹤0.01% 4723
2021
Q4 		$157K Buy
+26,138
New +$251K ﹤0.01% 4581

Geode Capital Management's GRCL Position: Q1 2024 in Review

Geode Capital Management sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 43,334 shares — an estimated $435K sold.

Geode Capital Management first reported a position in GRCL in Q4 2021 and held it in 9 quarters. The position peaked at $435K in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

  • Geode Capital Management reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
  • Geode Capital Management sold 43,334 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $435K.
  • Geode Capital Management first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2021 and held it in 9 quarters.
  • Geode Capital Management's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $435K in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Geode Capital Management's 13F filing for Q1 2024, filed 13 May 2024.